SCHEMBL25862304

SCHEMBL25862304

CC(N)c1ccn(C[C@H]2CCCO2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ ALDH1A1 P00352 6/20 0.39
▸ USP2 O75604 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ HSD17B10 Q99714 3/20 0.37
▸ CASP1 P29466 2/20 0.37
▸ CASP7 P55210 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25617367 0.89 KDM4E (0.40) KMT2ACYP1A2CYP2C9CYP2C19TDP1
SCHEMBL25859573 0.89 KDM4E (0.40) KMT2ACYP1A2CYP2C9CYP2C19TDP1
SCHEMBL10141574 0.85 ALDH1A1 (0.37) KMT2ACYP1A2CYP2C9CYP2C19TDP1
SCHEMBL10174367 0.74 BRD4 (0.41) KMT2ACYP1A2CYP2C9CYP2C19TDP1
SCHEMBL24915274 0.74 KDM4E (0.42) KMT2ACYP1A2CYP2C9CYP2C19TDP1
SCHEMBL22497240 0.73 KDM4E (0.42) KMT2ACYP1A2CYP2C9CYP2C19TDP1
SCHEMBL11914063 0.71 CHRM2 (0.34) KDM4EALDH1A1USP2GAA
SCHEMBL13228826 0.69 ALDH1A1 (0.34) KMT2ACYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL24915276 0.69 FEN1 (0.48) KMT2ACYP2C9CYP2C19TDP1ALOX15
SCHEMBL22524842 0.68 KDM4E (0.37) KMT2ACYP1A2CYP2C9CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227470-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER VANDERBILT UNIVERSITY 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227470-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER KRAS, NRAS, TP53 KMT2A 832/4885CYP1A2 1616/4885CYP2C9 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback